TY - JOUR
T1 - Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom
T2 - A retrospective observational study (LuCaBIS)
AU - Andreas, Stefan
AU - Chouaid, Christos
AU - Danson, Sarah
AU - Siakpere, Obukohwo
AU - Benjamin, Laure
AU - Ehness, Rainer
AU - Dramard-Goasdoue, Marie Hélène
AU - Barth, Janina
AU - Hoffmann, Hans
AU - Potter, Vanessa
AU - Barlesi, Fabrice
AU - Chirila, Costel
AU - Hollis, Kelly
AU - Sweeney, Carolyn
AU - Price, Mark
AU - Wolowacz, Sorrel
AU - Kaye, James A.
AU - Kontoudis, Ilias
N1 - Publisher Copyright:
© 2018 GlaxoSmithKline Biologicals SA
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Objectives: New adjuvant treatments are being developed for patients with resected non-small cell lung cancer (NSCLC). Due to scarcity of real-world data available for treatment costs and resource utilization, health technology and cost-effectiveness assessments can be limited. We estimated the burden and cost-of-illness associated with completely resected stage IB-IIIA NSCLC in France, Germany and the United Kingdom (UK). Materials and methods: Eligible patients were aged ≥18 years with completely resected stage IB-IIIA NSCLC between August 2009 and July 2012. Patients (living or deceased) were enrolled at clinical sites by a systematic sampling method. Data were obtained from medical records and patient surveys. Direct, indirect and patient out-of-pocket expenses were estimated by multiplying resource use by country-specific unit costs. National annual costs were estimated based on disease prevalence data available from published sources. Results: 39 centers provided data from 831 patients of whom patient surveys were evaluable in 306 patients. Median follow-up was 26 months. The mean total direct costs per patient during follow-up were: €19,057 (France), €14,185 (Germany), and €8377 (UK). The largest cost drivers were associated with therapies received (€12,375 France; €3694 UK), and hospitalization/emergency costs (€7706 Germany). Monthly direct costs per patient were the highest during the distant metastasis/terminal illness phase in France (€15,562) and Germany (€6047) and during the adjuvant treatment period in the UK (€2790). Estimated mean total indirect costs per patient were: €696 (France), €2476 (Germany), and €1414 (UK). Estimates for the annual national direct cost were €478.4 million (France), €574.6 million (Germany) and €325.8 million (UK). Conclusion: To our knowledge, this is the first comprehensive study describing the burden of illness for patients with completely resected stage IB-IIIA NSCLC. The economic burden was substantial in all three countries. Treatment of NSCLC is associated with large annual national costs, mainly incurred during disease progression.
AB - Objectives: New adjuvant treatments are being developed for patients with resected non-small cell lung cancer (NSCLC). Due to scarcity of real-world data available for treatment costs and resource utilization, health technology and cost-effectiveness assessments can be limited. We estimated the burden and cost-of-illness associated with completely resected stage IB-IIIA NSCLC in France, Germany and the United Kingdom (UK). Materials and methods: Eligible patients were aged ≥18 years with completely resected stage IB-IIIA NSCLC between August 2009 and July 2012. Patients (living or deceased) were enrolled at clinical sites by a systematic sampling method. Data were obtained from medical records and patient surveys. Direct, indirect and patient out-of-pocket expenses were estimated by multiplying resource use by country-specific unit costs. National annual costs were estimated based on disease prevalence data available from published sources. Results: 39 centers provided data from 831 patients of whom patient surveys were evaluable in 306 patients. Median follow-up was 26 months. The mean total direct costs per patient during follow-up were: €19,057 (France), €14,185 (Germany), and €8377 (UK). The largest cost drivers were associated with therapies received (€12,375 France; €3694 UK), and hospitalization/emergency costs (€7706 Germany). Monthly direct costs per patient were the highest during the distant metastasis/terminal illness phase in France (€15,562) and Germany (€6047) and during the adjuvant treatment period in the UK (€2790). Estimated mean total indirect costs per patient were: €696 (France), €2476 (Germany), and €1414 (UK). Estimates for the annual national direct cost were €478.4 million (France), €574.6 million (Germany) and €325.8 million (UK). Conclusion: To our knowledge, this is the first comprehensive study describing the burden of illness for patients with completely resected stage IB-IIIA NSCLC. The economic burden was substantial in all three countries. Treatment of NSCLC is associated with large annual national costs, mainly incurred during disease progression.
KW - Adjuvant therapy
KW - Cost of adverse event
KW - Direct cost
KW - Economic burden
KW - Indirect cost
KW - Non-small cell lung cancer (NSCLC)
UR - http://www.scopus.com/inward/record.url?scp=85049104908&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2018.06.007
DO - 10.1016/j.lungcan.2018.06.007
M3 - Article
C2 - 29961557
AN - SCOPUS:85049104908
SN - 0169-5002
VL - 124
SP - 298
EP - 309
JO - Lung Cancer
JF - Lung Cancer
ER -